Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease Pacientes com neuromielite óptica apresentam doença mais incapacitante que pacientes com esclerose múltipla, incluindo maior chance de falecerem de uma doença desmielinizante

Patients with neuromyelitis optica have a more severe disease than patients with relapsingremitting multiple sclerosis, including higher risk of dying of a demyelinating disease Pacientes com neuromielite óptica apresentam doença mais incapacitante que pacientes com esclerose múltipla, incluindo maior chance de falecerem de uma doença desmielinizante

Although neuromyelitis optica (NMO) is known to be a more severe disease than relapsing-remitting multiple sclerosis (RRMS), few studies comparing both conditions in a single center have been done. Methods: Comparison of our previously published cohort of 41 NMO patients with 177 RRMS patients foll...

Full description

Saved in:
Bibliographic Details
Main Authors: Denis Bernardi Bichuetti, Enedina Maria Lobato de Oliveira, Nilton Amorin de Souza, Mar Tintoré, Alberto Alain Gabbai
Format: Article
Language:English
Published: Thieme Revinter Publicações 2013-05-01
Series:Arquivos de Neuro-Psiquiatria
Subjects:
neuromielite óptica
esclerose múltipla
doenças desmielinizantes
fatores de risco
neuromyelitis optica
multiple sclerosis
demyelinating diseases
risk factors
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2013000500275
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although neuromyelitis optica (NMO) is known to be a more severe disease than relapsing-remitting multiple sclerosis (RRMS), few studies comparing both conditions in a single center have been done. Methods: Comparison of our previously published cohort of 41 NMO patients with 177 RRMS patients followed in the same center, from 1994 to 2007. Results: Mean age of onset was 32.6 for NMO and 30.2 for RRMS (p=0.2062) with mean disease duration of 7.4 years for NMO and 10.3 years for RRMS. Patients with NMO had a higher annualized relapse rate (1.0 versus 0.8, p=0.0013) and progression index (0.9 versus 0.6, p&#8810;0.0001), with more patients reaching expanded disability status scale (EDSS) 6.0 (39 versus 17%, p=0.0036). The odds ratio for reaching EDSS 6.0 and being deceased due to NMO in comparison to RRMS were, respectively, 3.14 and 12.15. Conclusion: Patients with NMO have a more severe disease than patients with RRMS, including higher risk of dying of a demyelinating disease.<br>Embora a neuromielite &#243;ptica (NMO) seja reconhecida como mais grave que a esclerose m&#250;ltipla remitente recorrente (EMRR), existem poucos estudos comparando as duas doen&#231;as em um &#250;nico centro. M&#233;todos: Compara&#231;&#227;o de nossa coorte publicada de 41 pacientes com NMO com 177 pacientes com EMRR seguidos no mesmo centro, de 1994 a 2007. Resultados: A m&#233;dia de idade inicial foi de 32,6 anos em NMO e 30,2 anos em EMRR (p=0,2062), com tempo m&#233;dio de doen&#231;a de 7,4 anos para NMO e 10,3 anos EMRR. Pacientes com NMO apresentaram maior taxa anualizada de surtos (1,0 versus 0,8, p=0,0013) e &#237;ndice de progress&#227;o (0,9 versus 0,6, p&#8810;0,0001), com mais pacientes atingindo EDSS 6,0 (39 versus 17%, p=0,0036). Os riscos relativos de se alcan&#231;ar 6,0 EDSS e falecer em decorr&#234;ncia de NMO em compara&#231;&#227;o com EMRR, foram, respectivamente, 3,14 e 12,15. Conclus&#227;o: Pacientes com NMO t&#234;m uma doen&#231;a mais grave do que os pacientes com EMRR, incluindo maior risco de morrer de uma doen&#231;a desmielinizante.
ISSN:0004-282X
1678-4227

Similar Items